ArticleRSC advances2025
Catalytic application of a bimetallic-organic framework with phosphorus acid groups in the preparation of pyrido[2,3-
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cu/ZnO@GO promoted green synthesis of novel dipyridopyrimidines: evaluation of biological activity and theoretical study of the mechanism using a DFT method.RSC advances · 2025Article
- Application of TMU-17-UR as a pillar-layered MOFs as a hydrogen bonding catalyst for the preparation of pyrazolo[3,4-RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, we prepared a bimetallic-organic framework (bimetallic-MOF) using Fe/Zr as metals. Subsequently, the bimetallic-MOF was functionalized with phosphorus acid groups to serve as a heterogeneous catalyst. The catalyst was characterized using various techniques, such as field emission scanning electron microscopy (FE-SEM), energy-dispersive X-ray spectroscopy (EDS), infrared spectroscopy (FT-IR), X-ray diffraction analysis (XRD) and Brunauer-Emmett-Teller (BET) surface area analysis. Due to its suitable surface area and pore size, this heterogeneous catalyst was used for the preparation of pyrido[2,3-
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.